Cytek Biosciences Reports First Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- US stock futures slip ahead of inflation report
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Wells Fargo raises oil price targets citing ongoing supply risks
Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c, Misses on Revenue; Offers FY25 Revenue Guidance
May 8, 2025 4:36 PM EDTCytek Biosciences, Inc. (NASDAQ: CTKB) reported Q1 EPS of ($0.09), $0.07 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $43.82 million.
GUIDANCE:
Cytek Biosciences, Inc. sees FY2025 revenue of $196-210 million, versus the... More
